Larson Financial Group’s Werewolf Therapeutics HOWL Stock Holding History

Larson Financial Group’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.7K	Hold	13,052	–	–	﹤0.01%	2805
2026 Q1	$10.9K	Hold	13,052	–	–	﹤0.01%	2198
2025 Q4	$8.27K	Buy	13,052 +3,052	+31%	+$3.71K	﹤0.01%	2225
2025 Q3	$19.7K	Hold	10,000	–	–	﹤0.01%	1655
2025 Q2	$10.9K	Hold	10,000	–	–	﹤0.01%	1777
2025 Q1	$9.72K	Hold	10,000	–	–	﹤0.01%	1647
2024 Q4	$14.8K	Buy	+10,000	New	+$20.4K	﹤0.01%	1337

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Verdad Advisers Boston, Massachusetts $104M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Larson Financial Group's HOWL Position: Q2 2026 in Review

Larson Financial Group held its Werewolf Therapeutics (HOWL) position steady in Q2 2026 at 13,052 shares worth $4.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

Larson Financial Group first reported a position in HOWL in Q4 2024 and has held it in 7 quarters since. The position peaked at $19.7K in Q3 2025. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

Larson Financial Group held 13,052 shares of Werewolf Therapeutics worth $4.7K as of Q2 2026.
Larson Financial Group left its Werewolf Therapeutics share count unchanged in Q2 2026.
Werewolf Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2805 holding.
Larson Financial Group first reported a position in Werewolf Therapeutics in Q4 2024 and has held it in 7 quarters since.
Larson Financial Group's Werewolf Therapeutics position peaked at $19.7K in Q3 2025.
45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.